Literature DB >> 32365417

Durability and outcome of endoscopic ultrasound-guided hepaticoduodenostomy using a fully covered metal stent for segregated right intrahepatic duct dilatation.

Ka Wing Ma1, Hoonsub So2, Dong Hui Cho3, Jin Sun Oh2, Tan To Cheung1, Do Hyun Park2.   

Abstract

BACKGROUND AND AIMS: Segregated right intrahepatic duct dilatation (IHD) results from complete obstruction of the biliary tract proximal to the hilar level. We aimed to evaluate long-term efficacy and safety of endoscopic ultrasound (EUS) hepaticoduodenostomy (HDS) in segregated right IHD.
METHODS: Consecutive patients who had undergone EUS-guided HDS with a fully covered self-expandable metal stent (FCSEMS) in an academic tertiary center were recruited. All patients had segregated right hepatic duct and failed drainage by endoscopic retrograde cholangiopancreatography (ERCP). Demographic data, endoscopic findings, procedure details, and outcome data were extracted from a prospectively maintained database.
RESULTS: From 2013 to 2017, there were 35 patients who had undergone EUS-guided HDS with a median follow-up duration of 169 (3-2091) days. Malignancy accounted for 71.4% of the ductal segregation, followed by surgical complication (17.1%). Technical and clinical success rate was 97.1% and 80%, respectively. Early adverse event (AE) happened in seven patients (20%), two of them required endoscopic reintervention, and no percutaneous transhepatic biliary drainage (PTBD) or surgery was performed because of AE. The median stent patency duration was 331 (3-1202) days. The median duration of fistula tract keeping was 1280 (3-1280) days. There was no significant difference in terms of patency rate with respect to whether the underlying pathology was benign or malignant (P = 0.776). EUS-guided HDS for right posterior sectional duct segregation was associated with higher 3-month stent patency rate when compared with right anterior sectional duct (79.1% vs 38.1%, P = 0.012).
CONCLUSION: Endoscopic ultrasound-guided HDS with an FCSEMS appears to be a safe and effective treatment as a viable alternative option to PTBD after failed ERCP. It creates a durable and reliable fistula tract for permanent access to an isolated ductal system, and this application deserves more attention.
© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  cholangiocarcinoma; endoscopic ultrasound; imaging and advanced technology/applied therapeutics

Year:  2020        PMID: 32365417     DOI: 10.1111/jgh.15089

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  2 in total

Review 1.  Role of therapeutic endoscopic ultrasound in gastrointestinal malignancy- current evidence and future directions.

Authors:  Jahnvi Dhar; Jayanta Samanta
Journal:  Clin J Gastroenterol       Date:  2022-01-14

2.  Hot topics in therapeutic EUS.

Authors:  Daniela Tabacelia; Alexandru Martiniuc; Daniela Elena Burtea; Adrian Saftoiu; Cezar Stroescu
Journal:  Endosc Ultrasound       Date:  2022 May-Jun       Impact factor: 5.275

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.